Skip to main content
Delfa

← All assets

E2814

4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

4

Ongoing

3

Recruiting

0

Completed

1

Sites

67

Countries

15

Endpoints

56

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 56 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1/2
1
Phase 2
1
Phase 2/3
2

Trials by status

Active, not recruiting
3
Completed
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
24
Other (unclassified)
8
Tau biomarkers
7
Fluid / digital biomarkers
7
Global cognition
4
Neurodegeneration biomarkers
2
Neuroimaging
2
Function / daily living
1
Amyloid biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 7 of 56 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

2

Phosphorylated tau 217 (p-tau217)Tau

2

Neurofilament light (NfL)Neurodeg.

2

Mini-Mental State Examination (MMSE)Cognition

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

4 of 4

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

E2814, Gantenerumab, Lecanemab, Solanezumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Active, not recruiting38Apr 202815
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

E2814, Lecanemab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Active, not recruiting36Apr 202812
NCT06602258A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

E2814, Lecanemab

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 2Active, not recruiting26Dec 2026-
NCT04971733A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

E2814

Alzheimer’s disease

PSEN1/PSEN2/APP mutation requiredPh 1/2Completed3May 20241results

Showing 1-4 of 4 trials